The Frequency Distribution of Apolipoprotein E Genetic Polymorphism and Relationship of Apolipoprotein E Genetic Polymorphism with Development of Coronary Artery Disease in Patients with Familial Hypercholesterolemia.
- Author:
Ki Hoon HAN
1
;
Seong Choon CHOE
;
Seok Yeon KIM
;
In Ho CHAE
;
Hyo Soo KIM
;
Dae Won SOHN
;
Byung Hee OH
;
Myoung Mook LEE
;
Young Bae PARK
;
Yun Shik CHOI
;
Young Woo LEE
Author Information
1. Heart Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
familial hypercholesterolemia;
apolipoprotein E;
polymorphism;
lovastatin
- MeSH:
Achilles Tendon;
Apolipoproteins E;
Apolipoproteins*;
Atherosclerosis;
Cholesterol;
Coronary Artery Disease*;
Coronary Vessels*;
Gene Frequency;
Genotype;
Humans;
Hydroxymethylglutaryl CoA Reductases;
Hyperlipoproteinemia Type II*;
Lipoproteins;
Lovastatin;
Polymorphism, Genetic*;
Triglycerides;
Xanthomatosis
- From:Korean Journal of Medicine
1998;55(6):1039-1048
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Apolipoprotein E genetic polymorphism was screened in subjects with FH to determine the genetic effects of Apo E polymorphism on basal cholesterol levels, severity of coronary atherosclerosis and response to lipid lowering therapy using HMG CoA reductase inhibitor. METHODS: Total 45 unrelated patients with FH (M:F= 24:21, 48.0/11.5yr.) were included in this study. Apolipoprotein E genetic polymorphism was screened. Clinical parameters were checked. Change of lipid profile to lovastatin,; 20mg/d (n=19), 40mg/d (n=12), and of Achilles tendon thickness were analysed. RESULTS: 1) Genotype frequencies of E2/3, 3/3, 4/3 were 8.9, 60.0, 31.1% respectively, and allele frequencies of epsilon2, epsilon3, and epsilon4 were 0.044, 0.800, and 0.155 respectively.2) Presence and degree of coronary atherosclerosis, the thickness of Achilles tendon and lipid levels were not significantly different by apolipoprotein E genotype.3) On multivariate study, age, triglyceride and cholesterol /high density lipoprotein were significantly related to presence of coroanry atherosclerosis. 4) Percent reduction of LDL-cholesterol by lovastatin was significantly low in subjects having E4/3 genotype than those having E3/3 genotype (p=0.05; 40mg/d), and the percent reduction of Achilles tendon thickness was significantly low in subjects having E4/3 genotype than those having E3/3 genotype (p=0.037; 20mg/d). CONCLUSION: The distribution of apolipoprotein E genotype in patients with familial hypercholesterolemia was not significantly different with that in normal subjects. But apolipoprotein E polymorphism may affect the reduction of LDL-cholesterol and Achilles tendon xanthoma with medication of HMG CoA reductase inhibitor in patients with familial hypercholesterolemia.
